DK175178B1 - Indretning til styret afgivelse af et eller flere aktive stoffer til et brugsmiljö og fremgangsmåde til fremstilling deraf - Google Patents

Indretning til styret afgivelse af et eller flere aktive stoffer til et brugsmiljö og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number: DK175178B1
Authority: DK; Denmark
Prior art keywords: weight; capsule; membrane; asymmetric; coating
Prior art date: 1988-08-30

Application number

DK198904244A

Other languages

Danish (da)

English (en)

Other versions

DK424489A (da

DK424489D0 (da

Inventor

John Robert Cardinal

Richard Wilker Korsmeyer

Scott Max Herbig

Jeelin Lo

Kelly Lincoln Smith

Avinash Govind Thombre

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-30

Filing date

1989-08-29

Publication date

2004-06-28

1989-08-29 Application filed by Pfizer filed Critical Pfizer

1989-08-29 Publication of DK424489D0 publication Critical patent/DK424489D0/da

1990-03-01 Publication of DK424489A publication Critical patent/DK424489A/da

2004-06-28 Application granted granted Critical

2004-06-28 Publication of DK175178B1 publication Critical patent/DK175178B1/da

Links

239000013543 active substance Substances 0.000 title claims abstract description 65
238000013270 controlled release Methods 0.000 title claims abstract description 11
238000000034 method Methods 0.000 title claims description 142
230000008569 process Effects 0.000 title claims description 87
238000002360 preparation method Methods 0.000 title description 5
239000012528 membrane Substances 0.000 claims abstract description 309
230000003204 osmotic effect Effects 0.000 claims abstract description 120
238000009792 diffusion process Methods 0.000 claims abstract description 22
238000005086 pumping Methods 0.000 claims abstract description 19
239000002775 capsule Substances 0.000 claims description 395
238000000576 coating method Methods 0.000 claims description 259
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 249
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 219
239000011248 coating agent Substances 0.000 claims description 170
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 157
239000000126 substance Substances 0.000 claims description 114
229920002301 cellulose acetate Polymers 0.000 claims description 105
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 97
238000010791 quenching Methods 0.000 claims description 88
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 60
229920000642 polymer Polymers 0.000 claims description 60
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 57
239000011148 porous material Substances 0.000 claims description 54
229920002678 cellulose Polymers 0.000 claims description 51
239000011162 core material Substances 0.000 claims description 50
238000001035 drying Methods 0.000 claims description 40
239000001856 Ethyl cellulose Substances 0.000 claims description 39
229920001249 ethyl cellulose Polymers 0.000 claims description 39
235000019325 ethyl cellulose Nutrition 0.000 claims description 39
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
239000000546 pharmaceutical excipient Substances 0.000 claims description 33
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 26
239000003795 chemical substances by application Substances 0.000 claims description 26
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 18
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 12
239000001632 sodium acetate Substances 0.000 claims description 12
235000017281 sodium acetate Nutrition 0.000 claims description 12
239000002002 slurry Substances 0.000 claims description 11
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
241001465754 Metazoa Species 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 7
238000005507 spraying Methods 0.000 claims description 7
230000036772 blood pressure Effects 0.000 claims description 6
239000007921 spray Substances 0.000 claims description 6
238000001694 spray drying Methods 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
238000007873 sieving Methods 0.000 claims description 4
206010011224 Cough Diseases 0.000 claims description 3
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
230000001387 anti-histamine Effects 0.000 claims description 3
239000000739 antihistaminic agent Substances 0.000 claims description 3
239000002249 anxiolytic agent Substances 0.000 claims description 3
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 3
210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
239000008280 blood Substances 0.000 claims 1
210000004369 blood Anatomy 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
230000010030 glucose lowering effect Effects 0.000 claims 1
239000000243 solution Substances 0.000 description 209
YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 68
229960002906 trimazosin Drugs 0.000 description 67
239000000203 mixture Substances 0.000 description 54
229960001389 doxazosin Drugs 0.000 description 44
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 44
239000002904 solvent Substances 0.000 description 43
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 42
229960001381 glipizide Drugs 0.000 description 42
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
239000003814 drug Substances 0.000 description 36
239000000872 buffer Substances 0.000 description 35
230000015572 biosynthetic process Effects 0.000 description 33
229940079593 drug Drugs 0.000 description 33
239000011324 bead Substances 0.000 description 28
229920006217 cellulose acetate butyrate Polymers 0.000 description 24
238000012377 drug delivery Methods 0.000 description 24
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 22
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 22
239000008101 lactose Substances 0.000 description 22
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
239000000843 powder Substances 0.000 description 22
230000000968 intestinal effect Effects 0.000 description 20
239000000463 material Substances 0.000 description 19
229910052943 magnesium sulfate Inorganic materials 0.000 description 18
235000019341 magnesium sulphate Nutrition 0.000 description 18
235000010980 cellulose Nutrition 0.000 description 16
239000001913 cellulose Substances 0.000 description 16
230000002496 gastric effect Effects 0.000 description 16
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 14
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 14
239000010410 layer Substances 0.000 description 14
206010012601 diabetes mellitus Diseases 0.000 description 13
239000000284 extract Substances 0.000 description 13
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
230000035699 permeability Effects 0.000 description 12
239000002344 surface layer Substances 0.000 description 12
235000019359 magnesium stearate Nutrition 0.000 description 11
239000012047 saturated solution Substances 0.000 description 11
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 9
229960004592 isopropanol Drugs 0.000 description 9
229920002596 Polyethylene Glycol 900 Polymers 0.000 description 8
-1 pseudo-ephedrine hydrochlorides Chemical class 0.000 description 8
229920003084 Avicel® PH-102 Polymers 0.000 description 7
239000004372 Polyvinyl alcohol Substances 0.000 description 7
239000001361 adipic acid Substances 0.000 description 7
235000011037 adipic acid Nutrition 0.000 description 7
239000001527 calcium lactate Substances 0.000 description 7
235000011086 calcium lactate Nutrition 0.000 description 7
229960002401 calcium lactate Drugs 0.000 description 7
238000009472 formulation Methods 0.000 description 7
229920002451 polyvinyl alcohol Polymers 0.000 description 7
238000009492 tablet coating Methods 0.000 description 7
239000002700 tablet coating Substances 0.000 description 7
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
229920002307 Dextran Polymers 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000002033 PVDF binder Substances 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 6
239000000945 filler Substances 0.000 description 6
229920002981 polyvinylidene fluoride Polymers 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
235000002906 tartaric acid Nutrition 0.000 description 6
239000011975 tartaric acid Substances 0.000 description 6
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
229920000623 Cellulose acetate phthalate Polymers 0.000 description 5
239000000020 Nitrocellulose Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 5
229940081734 cellulose acetate phthalate Drugs 0.000 description 5
229920001220 nitrocellulos Polymers 0.000 description 5
229920003229 poly(methyl methacrylate) Polymers 0.000 description 5
239000004926 polymethyl methacrylate Substances 0.000 description 5
239000001069 triethyl citrate Substances 0.000 description 5
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 5
235000013769 triethyl citrate Nutrition 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
229920000219 Ethylene vinyl alcohol Polymers 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 4
238000005266 casting Methods 0.000 description 4
239000004715 ethylene vinyl alcohol Substances 0.000 description 4
RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
239000004014 plasticizer Substances 0.000 description 4
229920002492 poly(sulfone) Polymers 0.000 description 4
229920002635 polyurethane Polymers 0.000 description 4
239000004814 polyurethane Substances 0.000 description 4
238000001223 reverse osmosis Methods 0.000 description 4
238000007789 sealing Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
206010001497 Agitation Diseases 0.000 description 3
229920008347 Cellulose acetate propionate Polymers 0.000 description 3
239000004952 Polyamide Substances 0.000 description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
238000013019 agitation Methods 0.000 description 3
239000003472 antidiabetic agent Substances 0.000 description 3
239000008199 coating composition Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
238000007598 dipping method Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000007654 immersion Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000011068 loading method Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
229920002647 polyamide Polymers 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
229960003908 pseudoephedrine Drugs 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000001384 succinic acid Substances 0.000 description 3
229960000281 trometamol Drugs 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
SELZTOJHBRTCNM-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O SELZTOJHBRTCNM-UHFFFAOYSA-N 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229920003086 cellulose ether Polymers 0.000 description 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
230000001427 coherent effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000004205 dimethyl polysiloxane Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
229920006332 epoxy adhesive Polymers 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229940126904 hypoglycaemic agent Drugs 0.000 description 2
239000002917 insecticide Substances 0.000 description 2
238000010409 ironing Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229960003194 meglumine Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000009182 swimming Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
VPSXHKGJZJCWLV-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylpiperidin-4-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCN(CC1)CC VPSXHKGJZJCWLV-UHFFFAOYSA-N 0.000 description 1
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Natural products CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
229920012373 Elvamide® 8063 Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229920010177 Kynar® 460 Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000282849 Ruminantia Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
RFUZHZOLHOAGIX-UHFFFAOYSA-N acetic acid;2-chloroacetic acid Chemical compound CC(O)=O.OC(=O)CCl RFUZHZOLHOAGIX-UHFFFAOYSA-N 0.000 description 1
JVIUIOWKTNJXAJ-UHFFFAOYSA-N acetic acid;2-ethoxy-2-oxoacetic acid Chemical compound CC(O)=O.CCOC(=O)C(O)=O JVIUIOWKTNJXAJ-UHFFFAOYSA-N 0.000 description 1
YMNMXQILQOXZPB-UHFFFAOYSA-N acetic acid;4-methylbenzenesulfonic acid Chemical compound CC(O)=O.CC1=CC=C(S(O)(=O)=O)C=C1 YMNMXQILQOXZPB-UHFFFAOYSA-N 0.000 description 1
WOOJRPBCEMEHLS-UHFFFAOYSA-N acetic acid;butane-1-sulfonic acid Chemical compound CC(O)=O.CCCCS(O)(=O)=O WOOJRPBCEMEHLS-UHFFFAOYSA-N 0.000 description 1
CBICCXFXCXELAR-UHFFFAOYSA-N acetic acid;ethyl hydrogen carbonate Chemical compound CC(O)=O.CCOC(O)=O CBICCXFXCXELAR-UHFFFAOYSA-N 0.000 description 1
ZXPJBQLFCRVBDR-UHFFFAOYSA-N acetic acid;methanesulfonic acid Chemical compound CC(O)=O.CS(O)(=O)=O ZXPJBQLFCRVBDR-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000011149 active material Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000007605 air drying Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
238000005422 blasting Methods 0.000 description 1
238000009835 boiling Methods 0.000 description 1
ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
229960000725 brompheniramine Drugs 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
229960001803 cetirizine Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000012320 chlorinating reagent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000001877 deodorizing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010612 desalination reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
ZDIGNSYAACHWNL-HNNXBMFYSA-N dexbrompheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 ZDIGNSYAACHWNL-HNNXBMFYSA-N 0.000 description 1
229960002691 dexbrompheniramine Drugs 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000009506 drug dissolution testing Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000001761 ethyl methyl cellulose Substances 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000005243 fluidization Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000008246 gaseous mixture Substances 0.000 description 1
230000002070 germicidal effect Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
229960000930 hydroxyzine Drugs 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940050176 methyl chloride Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229940111688 monobasic potassium phosphate Drugs 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000005192 partition Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
239000003016 pheromone Substances 0.000 description 1
239000005648 plant growth regulator Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000001878 scanning electron micrograph Methods 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229960001407 sodium bicarbonate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000009987 spinning Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000003021 water soluble solvent Substances 0.000 description 1
239000003232 water-soluble binding agent Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Preparation (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Executing Machine-Instructions (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Materials For Medical Uses (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

DK198904244A 1988-08-30 1989-08-29 Indretning til styret afgivelse af et eller flere aktive stoffer til et brugsmiljö og fremgangsmåde til fremstilling deraf DK175178B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23837188A	1988-08-30	1988-08-30
US23837188		1988-08-30

Publications (3)

Publication Number	Publication Date
DK424489D0 DK424489D0 (da)	1989-08-29
DK424489A DK424489A (da)	1990-03-01
DK175178B1 true DK175178B1 (da)	2004-06-28

Family

ID=22897578

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198904244A DK175178B1 (da)	1988-08-30	1989-08-29	Indretning til styret afgivelse af et eller flere aktive stoffer til et brugsmiljö og fremgangsmåde til fremstilling deraf

Country Status (26)

Country	Link
EP (1)	EP0357369B1 (de)
JP (1)	JPH07112971B2 (de)
KR (1)	KR920008701B1 (de)
CN (2)	CN1058387C (de)
AT (1)	ATE89162T1 (de)
AU (1)	AU615104B2 (de)
CA (1)	CA1338552C (de)
CZ (1)	CZ277763B6 (de)
DD (1)	DD289466A5 (de)
DE (1)	DE68906488T2 (de)
DK (1)	DK175178B1 (de)
EG (1)	EG19189A (de)
ES (1)	ES2041006T3 (de)
FI (1)	FI102515B1 (de)
HU (1)	HU222245B1 (de)
IE (1)	IE62859B1 (de)
IL (1)	IL91398A (de)
MX (1)	MX173942B (de)
MY (1)	MY104183A (de)
NO (1)	NO179232C (de)
NZ (1)	NZ230470A (de)
PL (1)	PL163079B1 (de)
PT (1)	PT91560B (de)
RU (2)	RU1837873C (de)
YU (1)	YU47422B (de)
ZA (1)	ZA896586B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4962128A (en) *	1989-11-02	1990-10-09	Pfizer Inc.	Method of treating anxiety-related disorders using sertraline
JPH0794379B2 (ja) *	1990-08-07	1995-10-11	ファイザー・インコーポレーテッド	放出製剤における界面重合膜の使用方法
WO1992005775A1 (en) *	1990-09-28	1992-04-16	Pfizer Inc.	Dispensing device containing a hydrophobic medium
JPH0733645A (ja) *	1992-05-28	1995-02-03	Elan Corp Plc	錠剤製剤
TW235239B (de) *	1992-11-20	1994-12-01	Pfizer
CA2150019C (en) *	1992-11-30	1999-01-05	Scott M. Herbig	Supported liquid membrane delivery devices
US5358502A (en) *	1993-02-25	1994-10-25	Pfizer Inc	PH-triggered osmotic bursting delivery devices
EP0758244B2 (de) *	1994-05-06	2008-02-13	Pfizer Inc.	Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5798119A (en) *	1995-06-13	1998-08-25	S. C. Johnson & Son, Inc.	Osmotic-delivery devices having vapor-permeable coatings
EP0811374A1 (de)	1996-05-29	1997-12-10	Pfizer Inc.	Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
WO1999001121A1 (en) *	1997-07-01	1999-01-14	Pfizer Inc.	Sertraline salts and sustained-release dosage forms of sertraline
UA63953C2 (uk) *	1997-07-01	2004-02-16	Пфайзер Продактс Інк.	Дозована форма уповільненого вивільнення, що містить сертралін, (варіанти) та спосіб лікування (варіанти)
DE19814256A1 (de) *	1998-03-31	1999-10-07	Asta Medica Ag	Feste, schnellzerfallende Cetirizin-Formulierungen
HK1040910B (en) *	1998-11-12	2009-06-26	Smithkline Beecham Plc	Pharmaceutical composition for modified release of an insulin sensitiser and metformin
US6056976A (en) *	1998-11-12	2000-05-02	Leiras Oy	Elastomer, its preparation and use
RU2153930C1 (ru) *	1999-02-02	2000-08-10	ООО Научно-исследовательская фирма "Ультрасан"	Сорбционная система с регулируемой десорбцией
AU4709000A (en) *	1999-05-17	2000-12-05	Dow Chemical Company, The	Process for making cellulose ether capsules with organic acids
GB9923045D0 (en) *	1999-09-29	1999-12-01	Novartis Ag	New oral formulations
US20030175349A1 (en) *	2001-01-30	2003-09-18	Council Of Scientific And Industrial Research	Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
WO2003084511A1 (en)	2002-04-04	2003-10-16	Pfizer Products Inc.	Palatable chewable tablet
US20040043067A1 (en) *	2002-06-19	2004-03-04	Salamone Joseph C.	Fluorosiloxane matrix controlled diffusion drug delivery systems
AU2003260336C1 (en) *	2002-07-29	2008-05-29	Glaxo Group Limited	Sustained release formulations comprising lamotrigine
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
US7611728B2 (en) *	2003-09-05	2009-11-03	Supernus Pharmaceuticals, Inc.	Osmotic delivery of therapeutic compounds by solubility enhancement
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
NZ728442A (en)	2004-10-21	2018-05-25	Adare Pharmaceuticals Inc	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) *	2004-11-12	2006-05-18	Eurand Pharmaceuticals Limited	Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
JP2009500339A (ja) *	2005-06-29	2009-01-08	アルザ・コーポレーシヨン	浸透性剤形のための低下された乾燥時間を提供する半透過性組成物
CN101583620B (zh)	2005-11-28	2016-08-17	马里纳斯医药公司	加奈索酮组合物及其制备和使用方法
KR20090007568A (ko) *	2006-04-24	2009-01-19	화이자 프로덕츠 인코포레이티드	약물 전달 장치용 비대칭 막
EP2248541B1 (de) *	2009-05-07	2018-10-31	Biotronik Ag	Medikamentenbeschichteter ballonkatheter und verfahren zur herstellung desselben
CN101773484B (zh) *	2009-05-12	2013-12-25	沈阳药科大学	胃漂浮渗透泵型非匀质膜胶囊缓控释系统及其制备方法
WO2011039686A1 (en)	2009-09-30	2011-04-07	Pfizer Inc.	Latrepirdine oral sustained release dosage forms
AU2010325746B2 (en)	2009-12-02	2016-02-25	Adare Pharmaceuticals S.R.L.	Fexofenadine microcapsules and compositions containing them
US10898865B2 (en) *	2013-01-31	2021-01-26	American University In Cairo (AUC)	Polymer-carbon nanotube nanocomposite porous membranes
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
WO2021014360A1 (en)	2019-07-23	2021-01-28	Pfizer Inc.	Oral modified release dosage forms
WO2021094953A1 (en)	2019-11-14	2021-05-20	Pfizer Inc.	1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
AU2021217209A1 (en)	2020-02-03	2022-09-29	Kenvue Brands Llc	A single layer chewable tablet comprising cetirizine
CN117752838A (zh) *	2023-12-14	2024-03-26	上海应用技术大学	一种摩擦释香微胶囊及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL271831A (de) *	1960-11-29
DE3167521D1 (en) *	1981-01-22	1985-01-17	Capsugel Ag	A process for producing a pharmaceutical capsule having enteric properties
NZ206600A (en) *	1983-05-11	1987-01-23	Alza Corp	Osmotic drug delivery device
GB8322007D0 (en) *	1983-08-16	1983-09-21	Wellcome Found	Pharmaceutical delivery system
US4684524A (en) *	1984-03-19	1987-08-04	Alza Corporation	Rate controlled dispenser for administering beneficial agent
DE10075031I2 (de) *	1984-08-17	2004-07-01	Wellcome Found	Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy

1989
- 1989-08-23 IL IL9139889A patent/IL91398A/en not_active IP Right Cessation
- 1989-08-28 MY MYPI89001180A patent/MY104183A/en unknown
- 1989-08-28 PT PT91560A patent/PT91560B/pt not_active IP Right Cessation
- 1989-08-28 CZ CS895011A patent/CZ277763B6/cs not_active IP Right Cessation
- 1989-08-28 CA CA000609559A patent/CA1338552C/en not_active Expired - Lifetime
- 1989-08-29 NO NO893450A patent/NO179232C/no unknown
- 1989-08-29 AU AU40891/89A patent/AU615104B2/en not_active Ceased
- 1989-08-29 KR KR1019890012295A patent/KR920008701B1/ko not_active Expired
- 1989-08-29 ZA ZA896586A patent/ZA896586B/xx unknown
- 1989-08-29 DK DK198904244A patent/DK175178B1/da not_active IP Right Cessation
- 1989-08-29 IE IE277189A patent/IE62859B1/en not_active IP Right Cessation
- 1989-08-29 AT AT89308716T patent/ATE89162T1/de not_active IP Right Cessation
- 1989-08-29 FI FI894046A patent/FI102515B1/fi not_active IP Right Cessation
- 1989-08-29 YU YU165789A patent/YU47422B/sh unknown
- 1989-08-29 DE DE8989308716T patent/DE68906488T2/de not_active Expired - Lifetime
- 1989-08-29 EP EP89308716A patent/EP0357369B1/de not_active Expired - Lifetime
- 1989-08-29 DD DD89332166A patent/DD289466A5/de not_active IP Right Cessation
- 1989-08-29 RU SU894742025A patent/RU1837873C/ru active
- 1989-08-29 HU HU8904493A patent/HU222245B1/hu active IP Right Grant
- 1989-08-29 CN CN89106969A patent/CN1058387C/zh not_active Expired - Fee Related
- 1989-08-29 EG EG42189A patent/EG19189A/xx active
- 1989-08-29 NZ NZ230470A patent/NZ230470A/xx unknown
- 1989-08-29 ES ES198989308716T patent/ES2041006T3/es not_active Expired - Lifetime
- 1989-08-30 PL PL89281220A patent/PL163079B1/pl not_active IP Right Cessation
- 1989-08-30 MX MX017371A patent/MX173942B/es unknown
- 1989-08-30 JP JP1224335A patent/JPH07112971B2/ja not_active Expired - Lifetime
1992
- 1992-02-12 RU SU925010894A patent/RU2093147C1/ru not_active IP Right Cessation
1995
- 1995-09-14 CN CN95115731A patent/CN1125573A/zh active Pending

Also Published As

Publication number	Publication date
DD289466A5 (de)	1991-05-02
PT91560B (pt)	1995-05-04
YU165789A (en)	1992-05-28
ZA896586B (en)	1991-04-24
EP0357369A2 (de)	1990-03-07
NO893450D0 (no)	1989-08-29
MX173942B (es)	1994-04-11
JPH07112971B2 (ja)	1995-12-06
FI894046L (fi)	1990-03-01
RU1837873C (ru)	1993-08-30
ATE89162T1 (de)	1993-05-15
IE62859B1 (en)	1995-03-08
KR900002821A (ko)	1990-03-23
JPH02174713A (ja)	1990-07-06
KR920008701B1 (ko)	1992-10-08
DK424489A (da)	1990-03-01
CN1058387C (zh)	2000-11-15
RU2093147C1 (ru)	1997-10-20
ES2041006T3 (es)	1993-11-01
NO179232B (no)	1996-05-28
CZ277763B6 (en)	1993-04-14
IL91398A (en)	1994-05-30
FI102515B (fi)	1998-12-31
DE68906488T2 (de)	1993-09-09
CN1125573A (zh)	1996-07-03
MY104183A (en)	1994-02-28
YU47422B (sh)	1995-03-27
DE68906488D1 (de)	1993-06-17
AU615104B2 (en)	1991-09-19
NO893450L (no)	1990-03-01
EP0357369A3 (de)	1991-10-02
EP0357369B1 (de)	1993-05-12
AU4089189A (en)	1990-05-31
NO179232C (no)	1996-09-04
FI102515B1 (fi)	1998-12-31
CS501189A3 (en)	1992-12-16
DK424489D0 (da)	1989-08-29
PL163079B1 (pl)	1994-02-28
HU222245B1 (hu)	2003-05-28
CN1042072A (zh)	1990-05-16
NZ230470A (en)	1991-06-25
IE892771L (en)	1990-02-28
PT91560A (pt)	1990-03-30
IL91398A0 (en)	1990-04-29
CA1338552C (en)	1996-08-27
FI894046A0 (fi)	1989-08-29
HUT74086A (en)	1996-11-28
EG19189A (en)	1994-11-30

Legal Events

Date	Code	Title	Description
2007-03-26	PBP	Patent lapsed	Country of ref document: DK

Publication	Publication Date	Title
DK175178B1 (da)	2004-06-28	Indretning til styret afgivelse af et eller flere aktive stoffer til et brugsmiljö og fremgangsmåde til fremstilling deraf
US5612059A (en)	1997-03-18	Use of asymmetric membranes in delivery devices
BE1001101A5 (fr)	1989-07-11	Forme de dosage pour le traitement des maladies cardiovasculaires.
US5178868A (en)	1993-01-12	Dosage form
DE69524214T3 (de)	2008-05-15	Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
CN101518517B (zh)	2014-11-26	药物剂量逐渐增加的剂型
CA2148837C (en)	1998-07-14	Delivery device having encapsulated excipients
US4915952A (en)	1990-04-10	Composition comprising drug, HPC, HPMC and PEO
FR2523441A1 (fr)	1983-09-23	Dispositif therapeutique osmotique pour la distribution de deux substances differentes
FR2545721A1 (fr)	1984-11-16	Dispositif osmotique pour la liberation de matieres dans un milieu d'utilisation
PT98571B (pt)	1999-03-31	Dispositivos para a libertacao controlada que utilizam membranas polimerizadas interfacialmente e de processos para a sua preparacao
JPH0647529B2 (ja)	1994-06-22	不活性なコア部を有する浸透圧利用薬剤投与具
FR2554001A1 (fr)	1985-05-03	Capsule osmotique pour l'apport de substances actives a un milieu environnant
FR2523442A1 (fr)	1983-09-23	Dispositif therapeutique distribuant simultanement deux solutions pharmaceutiques
CA2000932C (en)	1999-12-28	Oral pharmaceutical controlled release multiple unit dosage form
KR100527335B1 (ko)	2005-11-09	서방형 약물 전달 기구
MXPA05000206A (es)	2005-12-05	Forma de dosificiacion oral que comprende una formulacion liquida de agente activo y liberacion controlada de la misma mediante una composicion osmotica expansible.
JP2007520421A (ja)	2007-07-26	経口投与用放出制御型薬物送達システム
NZ231093A (en)	1992-06-25	Sustained-release formulation comprising units coated with an insoluble polymer containing pore-creating substances